Raffaele Califano comments on the CASPIAN trial of front-line durvalumab plus chemotherapy in extensive-stage small-cell lung cancer, and puts the findings in context of the IMpower133 study of atezolizumab in the same setting (3:30).
13-09-2019 | Small-cell lung cancer | Video | Article